2021-09-28 Comments Off on Novel polyclonal antibody therapy meets the criteria for graduation to phase 3 in ACTIV-2 trial Novel polyclonal antibody therapy meets the criteria for graduation to phase 3 in ACTIV-2 trial The AIDS Clinical Trials Group (ACTG), the largest global HIV
